A Billion dollar boom in RNA Based Therapeutics Market to reach $1.2 billion by 2020, registering a CAGR of 28.4%.
Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/546?utm_source=openpr&utm_medium=Niranjan
Despite being in the clinical research phase, the RNA based therapeutics is been explored as a promising treatment option for the diseases which are difficult to treat. Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology and SMaRT technology. RNAi technology and antisense technology together are gaining prominence in the research industry, as these technologies provide base sequence to develop RNA drugs. RNAi technology works by causing destruction of specific mRNA molecules; whereas, antisense technology works by synthesizing a strand of RNA from the known gene sequence.
These newly synthesized RNA strands then itself binds to mRNA and make mRNA inactive. Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market. The other drivers include target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, critical issues in drug delivery, high cost of research, and high failure rates are some of the major hurdles for the companies working in this field.
Despite the restraints, RNA based therapeutics has the potential to grow due to increasing interest exhibited by the pharmaceutical industries for the commercialization of these therapies. Quark Pharmaceuticals, Inc. (USA), Alnylam Pharmaceuticals, Inc. (the USA), Dicerna Pharmaceuticals, Inc. (the USA), Tekmira Pharmaceuticals Corp. (Canada), Benitec Biopharma Limited (Australia), Genzyme Corporation (USA), ISIS Pharmaceuticals Inc (USA), Silence Therapeutics PLC (UK) and Cenix BioScience GmbH (Germany) are some of the key players in this market. ISIS Pharmaceuticals, Inc. (USA) has focused its research activities on antisense technology and developed antisense therapeutics, namely Mipomersen and Fomivirsen. This therapeutics is commercially available in the market and marketed as Kynamro and Vitravene respectively. Quark, Alnylam and silence therapeutics are other major players of this market with strong research pipeline in RNA based therapeutics.
Purchase Inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/546?utm_source=openpr&utm_medium=Niranjan
RNA based therapeutics market is segmented into technology, application, end-users, and geography. The technology segment is further categorized as enabling technologies and enabled technologies. The segment of enabling technologies comprises of Microarrays, Labeling, Purification, Linear amplification, qRT-PCR, and Inhibition; whereas, enabled technologies to include RNA interference technology (RNAi) and RNA antisense technology. Enabled technologies account for the largest market share due to their potential use in therapeutics. The market for RNA based therapeutics is dominated by RNA interference technology as numerous companies have exhibited their interest to develop RNA drugs using RNAi technology.
RNA based therapeutics have wide applications covering a variety of chronic conditions such as Cardiovascular, Kidney Diseases, Oncology, Infectious diseases, Metabolic disorders, and Others. The pipeline research is concentrated towards oncology and infectious diseases due to their high prevalence and failure of existing treatment to effectively treat these conditions. The end user market is segmented into research, therapeutics, and diagnostics. Currently, research and diagnostics segments are largely exploring the RNA technologies and therapies for the commercialization of RNA drugs.
Geographically, RNA based therapeutics market is segmented into North America, Europe, Asia-Pacific, and LAMEA. Potential regions of the respective geographies are strategically analyzed to provide country wise focus on RNA research activities. North America dominates the RNA based therapeutics followed by Europe and Asia-Pacific. The key market players belong to North America and are conducting extensive research to commercialize the therapeutics. Moreover, the growth in North America and Europe is primarily driven by substantial investment in research, advancement in RNA platform technologies, government support and availability of suitable infrastructure to develop the novel RNA based therapies. However, business dynamics in Asia-pacific is anticipated to offer tremendous opportunities to major players of this market as the cost of clinical research is less in this region as compared to North America and Europe.
An in-depth analysis of research and clinical developments within RNA based therapeutics market is provided and light is shed on market dynamics that would prove crucial in understanding the market.
Quantitative analysis of the current market and estimations through 2013-2020 would assist strategists to design business strategies to capitalize on the prevailing opportunities in the market.
Competitive structure of RNA based therapeutics market is analyzed through Porters Five Forces model and provides an in-depth understanding of the influencing factors for commercialization of RNA therapeutics.
The detailed study of the strategies of key leaders, partnerships, acquisitions and clinical trials in the RNA based therapeutics market would be informative for professionals in the corporate sector.
Pin-point analysis of geographic segments would assist in the identification of most profitable segments to capitalize on.
KEY MARKET SEGMENTS
RNA based therapeutics market is segmented into four major categories such as Technology, Application, End Users and Geography.
MARKET BY TECHNOLOGY:
RNA Interference (RNAi) technologies
Small interfering RNA (siRNA)
RNA antisense technologies
MARKET BY APPLICATION:
MARKET BY END USERS:
MARKET BY GEOGRAPHY:
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release A Billion dollar boom in RNA Based Therapeutics Market to reach $1.2 billion by 2020, registering a CAGR of 28.4%. here
News-ID: 1709771 • Views: 254
More Releases from Allied Market Research
Home Care Monitoring and Diagnostics Market to See Extensive Worldwide Growth
Global Home Care Monitoring and Diagnostics Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables). According to a new report published by Allied Market Research, titled, “Home Care Monitoring and Diagnostics Market by Product
Neuropeptide Y Receptor Market to Obtain Awesome Hike in Revenues
Global Neuropeptide Y Receptor Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables). According to a new report published by Allied Market Research, titled, “Neuropeptide Y Receptor Market by Product (Food Grade and Pharmaceutical
Infused Dried Fruits Market Size is Set for Rapid Growth and Industry Trend by 2 …
Infused dried fruits are infused with fruit sugar solution through osmotic pressure and dried at 60°C temperature. These fruits have low calories and have low added sugar. The infused dried fruit companies have to follow standards like HACCP, BRC, IFS, and ISO22000. The infused dried fruits are vegan products that have high vitamin C, and are gluten and GMO-free. These products are also suitable for diabetics because they do not
Plant-based Food Market Growing Demand, Production Scope and Revenue 2020 to 202 …
Plant-based food refers to the food products derived from plant sources, which include fruits, vegetables, whole grains, tofu, seeds, beans, lentils, and soy. Unlike a few years ago, plant-based foods are now available conveniently in most grocery stores. The plant-based foods niche market has grown into a completely mainstream industry, since the dominant meat consumers are have shifted their preference toward plant-based meat and dairy alternatives. Download Sample Report with
More Releases for RNA
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
Topics Presented this February 2018 at RNA Therapeutics
SMi’s RNA Therapeutics will be bringing a global presence from MHRA, The RNA Institute, MiNA Therapeutics, AstraZeneca R&D, GSK, Sanofi, CureVac and more. With an agenda full of exciting and new approaches, examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches and patenting RNA Therapeutics. www.therapeutics-rna.com/opr Spotlight: Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis? Have questions answered during
RNA Analysis Market worth 3.62 billion USD by 2021
RNA Analysis Market size was around USD 1.89 billion in 2016. It is expected to grow at a CAGR of 13.9% to reach USD 3.62 billion by 2021. The market is mainly driven by the increasing technological advancements, increasing investment in research and development by biotechnology and pharmaceutical companies, rising government and private funding, and growing preference for personalized medicines. However, lack of skilled professionals in the transcriptomics field and lack
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led